New hope for relapsed AML? early trial of BL-M11D1 begins
NCT ID NCT05924750
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-phase study tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants must have a specific marker (CD33) on their cancer cells and be in fairly good health otherwise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
NOT_YET_RECRUITINGHefei, Anhui, China
Contact
-
Beijing Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Hematology, the First Hospital of Harbin
NOT_YET_RECRUITINGHaerbin, Heilongjiang, China
Contact
-
Qilu Hospital of Shandong University
NOT_YET_RECRUITINGJinan, Shangdong, China
Contact
Contact
Contact
-
Shanghai Tongji Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Shengjing Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
Contact
-
West China Hospital，Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.